- Home
- SOPH vs INBX Comparison
SOPH vs INBX Comparison
Compare SOPH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- INBX
- Stock Information
- Founded
- SOPH 2011
- INBX 2010
- Country
- SOPH Switzerland
- INBX United States
- Employees
- SOPH N/A
- INBX N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- INBX Health Care
- Exchange
- SOPH Nasdaq
- INBX Nasdaq
- Market Cap
- SOPH 226.6M
- INBX 218.9M
- IPO Year
- SOPH 2021
- INBX 2020
- Fundamental
- Price
- SOPH $3.26
- INBX $13.92
- Analyst Decision
- SOPH Strong Buy
- INBX Hold
- Analyst Count
- SOPH 3
- INBX 1
- Target Price
- SOPH $7.00
- INBX N/A
- AVG Volume (30 Days)
- SOPH 21.3K
- INBX 81.4K
- Earning Date
- SOPH 11-05-2024
- INBX 11-14-2024
- Dividend Yield
- SOPH N/A
- INBX N/A
- EPS Growth
- SOPH N/A
- INBX N/A
- EPS
- SOPH N/A
- INBX 119.38
- Revenue
- SOPH $64,488,000.00
- INBX $1,568,000.00
- Revenue This Year
- SOPH $7.20
- INBX N/A
- Revenue Next Year
- SOPH $15.71
- INBX N/A
- P/E Ratio
- SOPH N/A
- INBX $0.12
- Revenue Growth
- SOPH 9.85
- INBX 19.24
- 52 Week Low
- SOPH $2.70
- INBX $10.80
- 52 Week High
- SOPH $7.37
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- SOPH 46.64
- INBX 38.33
- Support Level
- SOPH $3.06
- INBX $14.53
- Resistance Level
- SOPH $3.47
- INBX $15.24
- Average True Range (ATR)
- SOPH 0.18
- INBX 0.72
- MACD
- SOPH -0.00
- INBX -0.10
- Stochastic Oscillator
- SOPH 45.45
- INBX 19.16
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.